A blog about the intersection of medicine and business, produced by the members of the Medical Consumerism seminar at the University of Minnesota.
Tuesday, February 01, 2011
Is U of M department of psychiatry chair in the pocket of AstraZeneca?
Charles Schulz, the Chair of Psychiatry at the University of Minnesota, is under scrutiny for his controversial work with AstraZeneca and the suicide of a young man from St. Paul. Read about it here, in the City Pages.
1 comment:
Anonymous
said...
Very curious about Schulz's comment regarding the design of Seroquel study #132. He states that the study was designed to gain FDA approval for Seroquel XR. One can only guess that means there was no chance this time that the study would come back with negative results!! I guess that is real science, design a study strictly for marketing purposes and leave no chance that it could be negative. What a crock.
1 comment:
Very curious about Schulz's comment regarding the design of Seroquel study #132. He states that the study was designed to gain FDA approval for Seroquel XR. One can only guess that means there was no chance this time that the study would come back with negative results!! I guess that is real science, design a study strictly for marketing purposes and leave no chance that it could be negative. What a crock.
Post a Comment